Searchable abstracts of presentations at key conferences in endocrinology

ea0065in1.1 | Advances in understanding skeletal disease | SFEBES2019

Identifying new skeletal disease

Makitie Outi

Metabolic bone diseases encompass a large spectrum of disorders of bone strength, bone growth, or bone structure. Most of the disorders are caused by genetic defects and have onset prenatally or in childhood. The International classification of genetic skeletal disorders includes >450 disorders divided into 40 subgroups based on their clinical, radiographic and genetic features. The individual disorders are rare but collectively result in significant morbidity and pose a chall...

ea0059s4.3 | New treatments for bone disorders | SFEBES2018

Rare bone disorders: New genes, biology and therapeutic targets

Makitie Outi

Genetic discoveries in patients and families with rare bone disorders have highlighted the complexity of molecular mechanisms and cellular pathways governing normal bone development and homeostasis. More than 400 different forms of skeletal dysplasia have been described. Most of them result from single-gene defects, involving genes that are of major importance for a particular cellular event in skeletal development. Studies aiming to identify the involved pathways can enable d...

ea0056s8.1 | Bone fragility - from bench to clinic | ECE2018

Clinical spectrum of new monogenic forms of osteoporosis

Makitie Outi

Genetic factors play an important role in osteoporosis. Several monogenic forms of osteoporosis have been recognized. The most common of these is osteogenesis imperfecta (OI) in which dominantly inherited mutations in the genes encoding type I collagen (COL1A1 and COL1A2) are responsible for approximately 90% of the cases. Several rare autosomal recessive forms of OI have also been described. In these the defects lie in proteins involved in posttranslational modification of ty...

ea0016p97 | Bone and calcium | ECE2008

A new form of hereditary low-turnover osteoporosis in a 3-generation Finnish family

Laine Christine , Saarinen Anne , Laine Tero , Makitie Outi

Juvenile primary osteoporosis, unless diagnosed as osteogenesis imperfecta, has previously been considered a sporadic and self-limiting disease. New genetic findings, including osteoporosis-causing mutations in the LDL-receptor related protein (LRP) 5 and LRP6 genes, challenge this view. The pathogenesis of juvenile osteoporosis still remains largely unknown. We describe findings in a three-generation pedigree with a new form of autosomal dominant osteoporosis.<p class="ab...

ea0049oc10.5 | Bone &amp; Calcium Homeostasis | ECE2017

Gα11-Phe220Ser loss-of-function mutation causes familial hypocalciuric hypercalcemia type-2 (FHH2) by disrupting a hydrophobic cluster critical for G-protein signaling

Gorvin Caroline M. , Cranston Treena , Hannan Fadil M. , Valta Helena , Makitie Outi , Schalin-Jantti Camilla , Thakker Rajesh V.

Mutations of the calcium-sensing receptor (CaSR), G-protein alpha-11 subunit (Gα11), and adaptor protein-2 sigma subunit (AP2σ) resulting in a loss-of-function, cause familial hypocalciuric hypercalcemia types 1-3 (FHH1-3), respectively. We investigated a family with FHH (four affected and two unaffected members) for CaSR, Gα11 and AP2σ mutations, and identified a heterozygous Gα11 missense mutation, Phe220Ser, which is predicted to disrupt a cluster o...

ea0090p324 | Calcium and Bone | ECE2023

Non-genetic, non-pharmacologic risk factors for osteoporosis: an umbrella review of observational studies

Christou Maria , Markozannes Georgios , Christou Evangelos , Oei Ling , Tigas Stelios , Cianferotti Luisella , Goulis Dimitrios , Karasik David , Makitie Outi , Rivadeneira Fernando , Kiel Douglas , Ntzani Evangelia

Introduction: Osteoporosis is a prevalent skeletal disease associated with increased fracture risk, morbidity, and mortality. Several meta-analyses have investigated the association between non-genetic, non-pharmacologic factors and osteoporosis risk.Purpose: We aimed to perform an umbrella review of the literature to systematically evaluate the available evidence.Methods: Meta-analyses of observational studies evaluating the assoc...

ea0056gp175 | Parathyroid | ECE2018

Diagnosis and management of pseudohypoparathyroidism and related disorders: first international consensus statement

Mantovani Giovanna , Lecumberri Beatriz , Bastepe Murat , Monk David , de Sanctis Luisa , Thiele Susanne , Usardi Alessia , Ahmed Faisal , Bufo Roberto , Choplin Timothee , DeFilippo Gianpaolo , Devernois Guillemette , Eggermann Thomas , Elli Francesca , Freson Kathleen , Ramirez Aurora Garcia , Germain-Lee Emily , Groussin Lionel , Hamdy Neveen , Hanna Patrick , Hiort Olaf , Juppner Harald , Kamenicky Peter , Knight Nina , Kottler Marie-Laure , Le Norcy Elvire , Levine Michael A , Makitie Outi , Martin Regina , Martos-Moreno Gabriel Angel , Minagawa Masanori , Murray Philip , Pereda Arrate , Pignolo Robert , Rejnmark Lars , Rodado Rebecca , Rothenbuhler Anya , Saraff Vrinda , Shoemaker Ashley , Shore Eileen M , Silve Caroline , Turan Serap , Woods Philip , Zillikens M Carola , de Nanclares Guiomar Perez , Linglart Agnes

Pseudohypoparathyroidism (PHP) and related disorders lead to a wide spectrum of abnormal physical characteristics, neurocognitive and endocrine abnormalities that share a common PTH/PTHrP signaling pathway. The clinical and molecular overlap of PHP and related disorders lead to difficulties in clinical and molecular diagnosis which prompt to the possibility of incorrect management of these patients. PHP (including all subtypes), pseudoPHP, acrodysostosis and progressive osseou...